At the start of the new year, a wave of major project construction is surging across the Central Plains region. Autobio In Vitro Diagnostic Industrial Park, the largest IVD industrial park in China, is taking shape at an accelerated pace in Zhengzhou Economic Development Zone.
The rapid development of Autobio’s industrial park also epitomizes Zhengzhou’s strategy of “supporting high-quality development with high-quality projects.”
According to relevant officials from Zhengzhou Municipal Government, the city plans 523 provincial and municipal key projects in 2026, with a total investment of 743.89 billion yuan and an annual planned investment of 197.42 billion yuan. The government work report also clearly proposes strengthening innovation-driven development and accelerating the construction of a modern industrial system.
Autobio’s industrial park is positioned at a key node of this layout. It will not only be China’s largest in vitro diagnostic industrial base but also become a flagship industrial landmark for Zhengzhou in the biomedicine sector, cultivating a signature high-value-added industry.
A Flagship IVD Industrial Base Under Rapid Construction
As one of Henan Province’s “Three Batches” key construction projects, the IVD industrial park involves a total investment of approximately 6 billion yuan, covers 251 mu of land, and has a total construction area of 720,000 square meters. It is being built in three phases, including a R&D center, manufacturing center, large-scale automated cold storage, and China’s first laboratory medicine museum.
At present, Phase I and Phase II have been completed and put into operation. The main structure of Phase III has been fully finished and is undergoing interior decoration, with some staff already moving in. The headquarters building and reagent R&D base are expected to be fully renovated within this year. Once fully operational, it will become the largest IVD industrial base in China.
Leading Product Layout and Strong R&D Capabilities
As a leading enterprise in China’s IVD industry, Autobio’s products cover immunoassay, microbiology, biochemistry and other full-range testing fields, with early layout in precision diagnosis segments such as sequencing and mass spectrometry.Up to now, its products have been adopted by more than 2,600 tertiary hospitals nationwide, covering 64.8% of such institutions, and over 6,700 secondary and above hospitals. They are also exported to more than 100 countries and regions. With its complete production lines and full-range diagnostic capabilities, the company has gained opportunities to expand market share in centralized procurement.
In addition, the company maintains strong R&D investment. During the 14th Five-Year Plan period, its cumulative R&D investment exceeded 3 billion yuan, with the R&D ratio staying above 14% for many consecutive years, and more than 1,900 R&D personnel.By the end of 2025, Autobio had obtained 1,025 product registration (filing) certificates, including 223 magnetic particle chemiluminescence products, ranking first in the industry.The independently developed Autolas X‑1 series laboratory automation line has achieved the leap from “local brand” to “local R&D and manufacturing.” The Sikun series gene sequencer has also been approved for clinical use, realizing full-chain independent control.
Global Strategy and Future Development Vision
Notably, Autobio’s differentiated strategy focuses on chemiluminescence products for the Asian market and microbial mass spectrometry as a breakthrough for the high-end European market. In the first three quarters of 2025, the Asian market contributed over 40% of overseas sales, and the Latin American market’s share is increasing year by year.
This synergistic model – “cutting-edge R&D, manufacturing in Zhengzhou, global market” – is helping Autobio navigate pressures in the domestic market.
Zhang Ruifeng, Executive Deputy General Manager of Zhengzhou Autobio Engineering Co., Ltd., stated that in the future, Autobio will continue to increase R&D investment, focus on key technologies such as nucleic acid sequencing and mass spectrometry, and upgrade products toward precision diagnosis to consolidate development with technological innovation.Meanwhile, the company will further expand into emerging sectors such as autoimmunity and allergens, deepen the transformation of “precision manufacturing + high-end services”, accelerate international layout, and inject strong momentum into Henan’s high-quality development through the “R&D at the frontier, manufacturing in Zhengzhou” model.
